These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35259416)

  • 21. Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.
    Jiang Y; Zhao M; Xi J; Li J; Tang W; Zheng X
    Front Public Health; 2023; 11():1282374. PubMed ID: 37841712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
    Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
    [No Abstract]   [Full Text] [Related]  

  • 23. Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.
    Li W; Bai R; Qian L; Chen N; Zhao Y; Han F; Bai L; Li J; Yu Y; Cui J
    Asia Pac J Clin Oncol; 2021 Apr; 17(2):e40-e47. PubMed ID: 31957251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
    Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
    BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
    Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
    J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States.
    Tian W; Niu L; Wang Z; Lu R; Xiao G; Deng F; Tanzhu G; Zhou R
    Front Immunol; 2023; 14():1268070. PubMed ID: 37822936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-Line Durvalumab in Addition to Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer: A U.S.-Based Cost-Effectiveness Analysis.
    Lin S; Luo S; Gu D; Li M; Rao X; Wang C; Huang P; Xu X; Weng X
    Oncologist; 2021 Nov; 26(11):e2013-e2020. PubMed ID: 34431578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-line tremelimumab plus durvalumab and chemotherapy
    Liu W; Huo G; Chen P
    Front Pharmacol; 2023; 14():1163381. PubMed ID: 37547328
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population.
    Liu S; Graves N; Tan AC
    Lung Cancer; 2024 May; 191():107794. PubMed ID: 38636314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland.
    Barbier MC; Pardo E; Panje CM; Gautschi O; Lupatsch JE;
    Eur J Health Econ; 2021 Jul; 22(5):669-677. PubMed ID: 33745093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of pegfilgrastim in patients with non-small cell lung cancer receiving ramucirumab plus docetaxel in Japan.
    Kondo Y; Tachi T; Sakakibara T; Kato J; Kato A; Mizuno T; Miyake Y; Teramachi H
    Support Care Cancer; 2022 Aug; 30(8):6775-6783. PubMed ID: 35524869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic Cranial Irradiation Versus Observation in Radically Treated Stage III Non-Small-Cell Lung Cancer: A Randomized Phase III NVALT-11/DLCRG-02 Study.
    De Ruysscher D; Dingemans AC; Praag J; Belderbos J; Tissing-Tan C; Herder J; Haitjema T; Ubbels F; Lagerwaard F; El Sharouni SY; Stigt JA; Smit E; van Tinteren H; van der Noort V; Groen HJM
    J Clin Oncol; 2018 Aug; 36(23):2366-2377. PubMed ID: 29787357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
    Panje CM; Dedes KJ; Matter-Walstra K; Schwenkglenks M; Gautschi O; Siano M; Aebersold DM; Plasswilm L; Lupatsch JE;
    Radiother Oncol; 2018 Nov; 129(2):257-263. PubMed ID: 30104008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.
    Pouwels XGLV; van Mil D; Kieneker LM; Boersma C; van Etten RW; Evers-Roeten B; Heerspink HJL; Hemmelder MH; Langelaan MLP; Thelen MHM; Gansevoort RT; Koffijberg H
    EClinicalMedicine; 2024 Feb; 68():102414. PubMed ID: 38299045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of proton radiotherapy versus photon radiotherapy for non-small cell lung cancer patients: Exploring the model-based approach.
    Aldenhoven L; Ramaekers B; Degens J; Oberije C; van Loon J; Dingemans AC; De Ruysscher D; Joore M
    Radiother Oncol; 2023 Jun; 183():109417. PubMed ID: 36375562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
    Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
    Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
    JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China.
    Guan H; Sheng Y; Guo W; Han S; Shi L
    Adv Ther; 2019 May; 36(5):1114-1125. PubMed ID: 30900201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.